Dr. William Hauswirth and his collaborators share in a $1.2 million international award for developing a sight-restoring treatment

Published: September 6th, 2018

Category: News & Events

The 2018 Antonio Champalimaud Vision Award recognizes Hauswirth and his colleagues for developing the first successful gene therapy to cure an inherited human disease. The disease, Leber congenital amaurosis Type 2, or LCA 2, is caused by a genetic defect. The 1 million euro (approximately $1.2 million) award from the Portugal-based D. Anna de Sommer Champalimaud and Dr. Carlos Montez Champalimaud Foundation is shared with University of Pennsylvania and University College of London researchers.

Click here to access the original article